TABLE 64

Incremental cost-effectiveness ratios of increasing costs of triage strategies and not treating patients diagnosed as ‘at risk’

Increasing cost of triage strategy (£)InterventionCost (£)QALYsICER
+ 10GDx271919.7393–
OCT284019.741068,260
HRT-MRA286919.741483,488
HRT-GPS287919.7414Dominateda
Current practice295419.7415488,759
+ 13GDx273319.7393–
OCT285319.741068,229
HRT-MRA288319.741483,457
HRT-GPS289319.7414Dominateda
Current practice295419.7415409,713
+ 16GDx274719.7393–
OCT286719.741068,198
HRT-MRA289719.741483,426
HRT-GPS290619.7414Dominateda
Current practice295419.7415330,667
+ 19GDx276119.7393–
OCT288119.741068,167
HRT-MRA291019.741483,396
HRT-GPS292019.7414Dominateda
Current practice295419.7415251,620
+ 22GDx277519.7393–
OCT289519.741068,137
HRT-MRA292419.741483,365
HRT-GPS293419.7414Dominateda
Current practice295419.7415172,574
+ 25GDx278819.7393–
OCT290819.741068,106
HRT-MRA293819.741483,335
HRT-GPS294719.7414Dominateda
Current practice295419.741593,527
+ 28GDx280219.7393–
OCT292219.741068,075
HRT-MRA295219.741483,304
Current practice295419.741514,481
HRT-GPS296119.7414Dominateda
+ 31GDx281619.7393–
OCT293619.741068,044
Current practice295419.741534,813
HRT-MRA296519.7414Dominateda
HRT-GPS297519.7414Dominateda
+ 34GDx283019.7393–
OCT294919.741068,014
Current practice295419.74158882
HRT-MRA297919.7414Dominateda
HRT-GPS298919.7414Dominateda
+ 37GDx284319.7393–
Current practice295419.741548,341
OCT296319.7410Dominateda
HRT-MRA299319.7414Dominateda
HRT-GPS300219.7414Dominateda
+ 40GDx285719.73930
Current practice295419.741542,328
OCT297719.7410Dominateda
HRT-MRA300619.7414Dominateda
HRT-GPS301619.7414Dominateda
+ 43GDx287119.7393–
Current practice295419.741536,314
OCT299119.7410Dominateda
HRT-MRA302019.7414Dominateda
HRT-GPS303019.7414Dominateda
+ 46GDx288519.7393–
Current practice295419.741530,300
OCT300419.7410Dominateda
HRT-MRA303419.7414Dominateda
HRT-GPS304319.7414Dominateda
+ 49GDx289819.7393–
Current practice295419.741524,287
OCT301819.7410Dominateda
HRT-MRA304819.7414Dominateda
HRT-GPS305719.7414Dominateda
+ 52GDx291219.7393–
Current practice295419.741518,273
OCT303219.7410Dominateda
HRT-MRA306119.7414Dominateda
HRT-GPS307119.7414Dominateda
+ 55GDx292619.7393–
Current practice295419.741512,260
OCT304519.7410Dominateda
HRT-MRA307519.7414Dominateda
HRT-GPS308419.7414Dominateda
+ 58GDx294019.7393–
Current practice295419.74156246
OCT305919.7410Dominateda
HRT-MRA308919.7414Dominateda
HRT-GPS309819.7414Dominateda
+ 61GDx295419.7393–
Current practice295419.7415233
OCT307319.7410Dominateda
HRT-MRA310219.7414Dominateda
HRT-GPS311219.7414Dominateda
+ 64Current practice295419.7415–
GDx296719.7393Dominateda
OCT308719.7410Dominateda
HRT-MRA311619.7414Dominateda
HRT-GPS312619.7414Dominateda
+ 67Current practice295419.7415–
GDx298119.7393Dominateda
OCT310019.7410Dominateda
HRT-MRA313019.7414Dominateda
HRT-GPS313919.7414Dominateda
a

Dominated: an intervention is more costly but is less effective or as effective as an intervention that is less costly.

From: Appendix 7, Cost-effectiveness supplementary tables

Cover of Automated imaging technologies for the diagnosis of glaucoma: a comparative diagnostic study for the evaluation of the diagnostic accuracy, performance as triage tests and cost-effectiveness (GATE study)
Automated imaging technologies for the diagnosis of glaucoma: a comparative diagnostic study for the evaluation of the diagnostic accuracy, performance as triage tests and cost-effectiveness (GATE study).
Health Technology Assessment, No. 20.8.
Azuara-Blanco A, Banister K, Boachie C, et al.
Southampton (UK): NIHR Journals Library; 2016 Jan.
Copyright © Queen’s Printer and Controller of HMSO 2016. This work was produced by Azuara-Blanco et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.